iPSC Model for Fabry Disease Vascular Cell Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying Fabry disease and developing therapeutic agents are limited by the lack of a precise model that accurately replicates the disease's cardiovascular complications, and existing enzyme replacement therapies are unstable and prone to allergic reactions.
Innovation Solution
The development of induced pluripotent stem cells (iPSCs) from Fabry disease patient fibroblasts, which are differentiated into vascular cells, allowing for the study of Gb3 accumulation and the screening of therapeutic agents by mimicking the disease's pathophysiology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered to treat Fabry disease, then Gb3 accumulation is reduced, but the therapy is unstable in blood and causes allergic reactions
Solution Approach 1:
The patent creates induced pluripotent stem cells (iPSCs) from patient fibroblasts that replicate the disease state in a controlled laboratory environment. These iPSCs serve as a copy of the patient's cellular pathology, allowing therapeutic testing without administering unstable enzymes to the patient directly. The iPSC model copies the Gb3 accumulation phenotype while enabling safe therapeutic screening.
Solution Approach 2:
The iPSC model acts as an intermediary between the patient and therapeutic testing. Instead of directly administering recombinant enzymes to patients (which causes instability and allergic reactions), the patent uses iPSCs as an intermediate system to pre-screen and optimize therapeutic agents before clinical application. This intermediary model filters out harmful effects while preserving therapeutic efficacy.
2Measurement precision
If GLA knock-out mouse is used to study Fabry disease, then disease mechanism can be investigated, but the model cannot precisely replicate human cardiovascular complications
Solution Approach 1:
The patent copies human fibroblasts with the specific GLA mutation into iPSCs, creating a human cell model rather than relying on mouse models. This copying approach preserves human-specific cellular pathways and genetics, enabling precise replication of human cardiovascular complications while maintaining the disease mechanism under investigation.
Solution Approach 2:
The patent changes the species parameter from mouse to human by using human fibroblasts as the starting material for iPSC generation. This parameter change allows the model to replicate human-specific disease features and cardiovascular pathology that mouse models cannot capture, while still maintaining the essential GLA deficiency pathway for mechanistic study.
3Reliability
If recombinant enzymes are administered repeatedly to treat Fabry disease, then Gb3 accumulation is eliminated, but the enzymes are unstable in blood and cause allergic reactions
Solution Approach 1:
The patent creates a cellular copy system (iPSCs) that maintains the disease state without requiring repeated enzyme administration. The iPSC model copies the pathological Gb3 accumulation phenotype in a stable, non-progressive manner, eliminating the need for repeated therapeutic dosing while maintaining research efficacy.
Solution Approach 2:
The patent uses a disposable iPSC model system that can be cultured and differentiated multiple times without degradation. Unlike recombinant enzymes that degrade in blood, the iPSC model maintains stable genetic and phenotypic characteristics across passages, providing long-term stability for therapeutic screening without the instability issues of protein-based therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iPSC model effectively replicates Fabry disease symptoms, enabling the investigation of disease mechanisms and the screening of therapeutic agents, with Fabrazyme treatment significantly reducing Gb3 accumulation in vascular cells, thus providing a valuable tool for disease research and therapy development.
Implementation Method 1
Once the lysosomal enzyme is deficient because of GLA gene mutation, globotriaosylceramide (Gb3, CD77) which is the neutral glycosphingolipid known to be acting as a Shiga toxin receiver in Burkitt's lymphoma cells is excessively accumulated
Implementation Method 2
The intravenously injected enzyme is introduced in cells via mannose 6 phosphate (M6P) receiver in plasma membrane, and then further moves to lysosome. The administration of such therapeutic enzyme plays a key role in treating Fabry disease.
Data Source
AI summary
The present invention relates to an induced pluripotent stem cell model of Fabry disease, a preparation method thereof, and a use of the same for the study of Fabry disease development and for the screening of a therapeutic agent for the disease. Particularly, Fabry disease derived induced pluripotent stem cells (iPSCs), embryoid body (EB), and vascular cells were developed and differentiated from fibroblasts originated from Fabry disease patient, wherein the Fabry disease originated iPSCs displayed significantly reduced expression and activity of GLA protein therein, compared with the normal cells, resulting in the accumulation of globotriaosylceramide (Gb3, CD77). Also, the differentiation of vascular cells was induced from the Fabry disease originated iPSCs, and as a result the iPSCs were successfully differentiated into vascular endothelial cells and vascular smooth muscle cells with significantly expressing the marker protein. When the vascular endothelial cells and vascular smooth muscle cells were treated with Fabrazyme, the accumulation of Gb3 was significantly reduced, suggesting that the said cell model can be effectively used for the analysis/study of Fabry disease outbreak mechanism and for the screening of a therapeutic agent for the disease.